Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001839128 | SCV002099045 | uncertain significance | Larsen syndrome | 2021-03-22 | criteria provided, single submitter | clinical testing | The c.5059T>C (p.Tyr1687His) variant in exon 29 of 46 of FLNB has not been reported in affected individuals in the available literature. This variant is present in gnomADv3 at a low frequency (1/152238 heterozygote, allele frequency=6.56e-6), suggesting it is not a common benign variant in the populations represented in this database. In silico predictors suggest this variant is Benign (REVELscore: 0.2189) and Tolerated (SIFT score: 0.215). Given the current evidences regarding its pathogenicity, the c.5059T>C (p.Tyr1687His) variant identified in the FLNB gene is a Variant of uncertain significance. |
Labcorp Genetics |
RCV002542824 | SCV003023910 | likely benign | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004980741 | SCV005588215 | uncertain significance | Inborn genetic diseases | 2024-10-29 | criteria provided, single submitter | clinical testing | The c.5059T>C (p.Y1687H) alteration is located in exon 29 (coding exon 29) of the FLNB gene. This alteration results from a T to C substitution at nucleotide position 5059, causing the tyrosine (Y) at amino acid position 1687 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |